TY - JOUR AU - Ovilla-Martinez, Roberto AU - Cota-Rangel, Xochitl AU - De La Peña-Celaya, Jose AU - Alvarado-Zepeda, Mariana Alejandra AU - Jiménez Sastré, Alejandro AU - Azuara Forcelledo, Humberto AU - Ordoñez Rodriguez, Bernardino AU - Pulido Broca, Juan AU - Molina Jaimes, Aaron AU - Muñiz-Carvajal, Alejandro AU - Bahena García, Maria Magdalena AU - Cervera Ceballos, Eduardo AU - Zapata Canto, Nidia Paulina AU - García Mendez, Jorge Oscar AU - García Jímenez, Omar Noel AU - Salas Heredia, Jesus Alberto AU - Solis Soto, Javier AU - Villalobos Mendez, Ruben Alberto AU - Ignacio Ibarra, Gregorio AU - Ledesma de la Cruz, Cindy AU - Araujo Martinez, Nora AU - Juárez Lara, Jessi AU - Ceballos Zuñiga, Cecilio Omar AU - Villaseñor Pérez, Felipe Vicente AU - Herrera Garcia, Jose Carlos AU - Nuche Salazar, Patricia AU - Dominguez Paregrina, Alfredo AU - Arizpe Bravo, Bertha AU - Enciso Figueroa, Gabriela AU - Trujillo, Teresita AU - Miguel Álvarez, Adriana AU - García Gallegos, Diego de Jesús AU - Ortiz Arroyo, Alejandro AU - Solorzano Soto, Claudia Ivette AU - Jaramillo Ramírez, Hiram Javier AU - De la Cruz Hernández, Ibis AU - De Gante Martínez, Sergio AU - Montesinos Gómez, Guadalupe Esmeralda AU - Martínez Velasco, Silvia AU - García Graullera, Roberto AU - Vázquez López, Miguel Angel AU - Urbalejo Ceniceros, Victor Itaí AU - Lugo García, Yolanda AU - González Ávila, Ana Itamar AU - Duque Rodriguez, Jorge AU - Ruiz Luján, Rodolfo AU - Rodríguez Rivera, Violeta I. AU - Soberanes Ramírez, Lucio AU - Baez-Islas, Pamela Elena PY - 2022/01/31 Y2 - 2024/03/29 TI - Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world setting JF - The Journal of Infection in Developing Countries JA - J Infect Dev Ctries VL - 16 IS - 01 SE - Coronavirus Pandemic DO - 10.3855/jidc.15126 UR - https://jidc.org/index.php/journal/article/view/35192523 SP - 63-72 AB - <p>Introduction: Severe acute respiratory syndrome-related coronavirus (SARS-CoV-2) infection is characterised by a viral phase and a severe pro-inflammatory phase. The inhibition of the JAK/STAT pathway limits the pro-inflammatory state in moderate to severe COVID-19.</p><p>Methodology: We analysed the data obtained by an observational cohort of patients with SARS-CoV-2 pneumonia treated with ruxolitinib in 22 hospitals of Mexico. The applied dose was determined based on physician’s criteria. The benefit of ruxolitinib was evaluated using the 8-points ordinal scale developed by the NIH in the ACTT1 trial. Duration of hospital stay, changes in pro-inflammatory laboratory values, mortality, and toxicity were also measured.</p><p>Results: A total of 287 patients were reported at 22 sites in Mexico from March to June 2020; 80.8% received ruxolitinib 5 mg BID and 19.16% received ruxolitinib 10 mg BID plus standard of care. At beginning of treatment, 223 patients were on oxygen support and 59 on invasive ventilation. The percentage of patients on invasive ventilation was 53% in the 10 mg and 13% in the 5 mg cohort. A statistically significant improvement measured as a reduction by 2 points on the 8-point ordinal scale was described (baseline 5.39 ± 0.93, final 3.67± 2.98<em>, p = 0.0001</em>). There were 74 deaths. Serious adverse events were presented in 6.9% of the patients.</p><p>Conclusions: Ruxolitinib appears to be safe in COVID-19 patients, with clinical benefits observed in terms of decrease in the 8-point ordinal scale and pro-inflammatory state. Further studies must be done to ensure efficacy against mortality.</p> ER -